Word counts: Abstract (226); Importance (75); Text without figure legends and references (3,565) ABSTRACT 1 HPV16 E7 has long been noted to stabilize the TP53 tumor suppressor. However, the molecular 2 mechanism of TP53 stabilization by HPV16 E7 has remained obscure and can occur independent 3 of E2F regulated MDM2 inhibitor, p14 ARF . Here, we report that the Damage Induced Noncoding 4 (DINO) lncRNA (DINOL) is the missing link between HPV16 E7 and increased TP53 levels. 5 DINO levels are decreased in cells where TP53 is inactivated, either by HPV16 E6, expression 6 of a dominant negative TP53 minigene or by TP53 depletion. DINO levels are increased in 7 HPV16 E7 expressing cells. HPV16 E7 causes increased DINO expression independent of RB1 8 degradation and E2F1 activation. Similar to the adjacent CDKN1A locus, DINO expression is 9 regulated by the histone demethylase, KDM6A. DINO stabilizes TP53 in HPV16 E7 expressing 10 cells and as a TP53 transcriptional target, DINO levels further increase. Similar to other 11 oncogenes such as adenovirus E1A or MYC, HPV16 E7 expressing cells are sensitized to cell 12 death under conditions of metabolic stress and in the case of E7, this has been linked to TP53 13 activation. Consistent with earlier studies, we show that HPV16 E7 expressing keratinocytes are 14 highly sensitive to metabolic stress induced by the antidiabetic drug, metformin. Metformin 15 sensitivity of HPV16 E7 expressing cells is rescued by DINO depletion. This work identifies 16 DINO as a critical mediator TP53 stabilization and activation in HPV16 E7 expressing cells. 17 18
IMPORTANCE 19
Viral oncoproteins, including HPV16 E6 and E7 have been instrumental in elucidating the 20 activities of cellular signaling networks including those governed by the TP53 tumor suppressor. 21
Our study demonstrates that the long noncoding RNA DINO is the long sought missing link 22 between HPV16 E7 and elevated TP53 levels. Importantly, the TP53 stabilizing DINO plays a 23 critical role in the predisposition of HPV16 E7 expressing cells to cell death under metabolic 24 stress conditions from metformin treatment. The cancer-associated, high-risk human papillomavirus (HPV) E6 and E7 proteins have 31 oncogenic activities and are necessary for tumor induction and maintenance. These low-32 molecular weight proteins lack intrinsic enzymatic activities and function by subverting host 33 cellular regulatory networks (1, 2). Over the years, many potential cellular targets of the HPV E6 34 and E7 proteins have been identified. The main focus of these studies, however, has been on 35 identifying host cellular protein targets and the resulting dysregulation of protein coding 36 mRNAs. Protein coding genes, however, only constitute a minor fraction (<3%) of the human 37 transcriptome (3), and advances in next generation sequencing technologies have shown that 38 noncoding RNAs including microRNAs and long noncoding (lnc) RNAs, are also aberrantly 39 expressed in HPV E6 and/or E7 expressing cells (4) (5) (6) (7) . It is now firmly established that 40 noncoding RNAs are important regulators of a variety of cellular processes that drive specific 41 biological phenotypes (8-11). 42 43 Many viral proteins, including the E6 and E7 proteins encoded by high-risk HPVs have evolved 44 to modulate the TP53 tumor suppressor pathway (12). TP53 is critically involved in sensing 45 many forms of cellular stress, including those caused by viral infection or nutrient starvation. 46
Upon activation, TP53 is stabilized and elicits transcriptional programs that trigger cytostatic or 47 cytotoxic responses, including cycle arrest, senescence or apoptosis (13). Hence, TP53 levels and 48 activity are tightly regulated. A well-known regulator of TP53 is the MDM2 ubiquitin ligase. 49 MDM2 is a TP53 responsive gene, which in turns binds and targets TP53 for ubiquitin dependent 50 proteasomal degradation (14). MDM2 activity is regulated at multiple levels. One important 51 inhibitor of MDM2 is the p14 ARF protein, which is regulated by E2F transcription factors, the 52 downstream effectors of the retinoblastoma (RB1) tumor suppressor. 53
54
The E6 and E7 proteins encoded by high-risk HPVs, including HPV16, each modulate TP53 55 levels and activity. HPV16 E6 targets TP53 for proteasome mediated degradation through an 56 MDM2 independent mechanism that involves the E6-associated ubiquitin ligase, UBE3A 57 (E6AP) (15, 16). The ability of high-risk HPV E6 proteins to inhibit TP53 is thought to have 58 evolved from the necessity to counteract TP53 stabilization and activation triggered by 59 expression of the HPV E7 oncoprotein (17-22). Consequently, several other DNA tumor viruses, 60
including adenoviruses and many polyomaviruses that encode proteins that inactivate the RB1 61 tumor suppressor also encode proteins that dampen TP53 tumor suppressor activity. In the case 62 of the adenovirus E1A protein, TP53 stabilization was shown to be mediated by the E2F induced 63 MDM2 inhibitor, p14 ARF (23). Surprisingly, however, HPV16 E7 has been shown to stabilize 64 TP53 independently of p14 ARF (21) and, to this date, the mediator of HPV16 E7 mediated TP53 65 stabilization has remained elusive. 66
67
In recent years, it has been appreciated that various host cellular noncoding RNAs also function 68 as important regulators of the TP53 tumor suppressor pathway. In addition to microRNAs (24), 69 a variety of cellular lncRNAs have been identified as components of the TP53 signaling network 70 TP53 is inactivated either by the expression of the HPV16 E6 protein or by the dnTP53 C-97 terminal minigene (E6: 0.14 +/-0.01, p < 0.001, E6/E7: 0.22 +/-0.04, p < 0.001 and dnTP53: 98 0.28 +/-0.01, p < 0.001) ( Figure 1B ). This is consistent with a previous study that showed that 99 DINO expression is controlled by TP53 (28). In contrast, HPV16 E7 expressing HFKs, which, as 100 published previously (17, 20, 21), express high levels of TP53 ( Figure 1A ), expressed 101 significantly increased DINO levels (E7: 6.14 +/-0.14, p < 0.001) ( Figure 1B ). Hence, DINO 102 levels correlate with TP53 levels in HPV oncoprotein expressing cells. 103
104

TP53 driven DINO causes elevated TP53 levels in HPV16 E7 expressing cells 105
Given the correlation between DINO and TP53 levels in E7 expression cells, we next determined 106 whether DINO expression in HPV16 E7 expressing cells was driven by TP53. We transiently 107 depleted TP53 in control as well as in HPV16 E7 expressing human telomerase immortalized 108 HFKs (iHFKs) with a pool of TP53 targeting siRNAs. To assess the effect of TP53 depletion on 109 expression of TP53 target genes, we analyzed expression of CDKN1A (p21 CIP1 ) by western 110 blotting and qRT-PCR. As expected, CDKN1A protein and mRNA levels were decreased in 111 control and HPV16 E7 expressing cells upon TP53 depletion (Figure 2A, B) . Similarly, TP53 112 depletion also caused a significant decrease of DINO in control as well as in HPV16 E7 113 expressing cells (C: 0.09 +/-0.01, p < 0.001 and E7: 0.08 +/-0.02, p < 0.001) ( Figure 2B ). 114
115
To determine whether DINO may be the "missing link" that mediates TP53 stabilization in E7 116 expressing cells, we acutely depleted DINO in HPV16 E7 expressing iHFKs using doxycycline 117 regulated shRNA expression. Depletion of DINO after doxycycline treatment for 48 hours by 118 two different shRNAs each caused an approximately 50% decrease in TP53 levels in E7 8 CDKN1A gene were also decreased (sh-DINO1: 0.61 +/-0.01, p < 0.01, and sh-DINO2: 0.48 +/-121 0.02, p < 0.01) ( Figure 2D ). Hence, DINO levels accumulate in HPV16 E7 expressing cells as a 122 result of TP53 activation, and, in addition, they amplify TP53 stabilization and presumably TP53 123 activation in HPV16 E7 expressing cells. 124 125
TP53 and KDM6A, but not RB1 and E2F1 are the upstream regulators of DINO 126
Previous mutational studies with HPV16 E7 revealed that TP53 stabilization by HPV16 E7 127 required similar sequences as those that are necessary for RB1 destabilization (20). Consistent 128 with these earlier studies, the RB1 binding and degradation defective HPV16 E7 DDLYC mutant 129 failed to stabilize TP53 ( Figure 3A) . Similarly, unlike wild type HPV16 E7, expression of 130 HPV16 E7 DDLYC also failed to upregulate DINO in IMR90s normal human diploid lung 131 fibroblasts (E7: 7.03 +/-1.28, p < 0.01 and DDLYC: 1.00 +/-0.18, non-significant) ( Figure 3B ). 132
To determine whether DINO levels in HPV16 E7 expressing cells were increased as a 133 consequence of RB1 tumor suppressor degradation and E2F activation, we transiently depleted 134 RB1 and E2F1 in control and HPV16 E7 expressing iHFKs by transfecting the corresponding 135 siRNA pools. Transfections of a TP53 targeting siRNA pool and a non-targeting siRNA pool 136 were used as positive and negative controls, respectively. Depletion of the corresponding 137 proteins was assessed by western blotting ( Figure 3C ). Whereas, as expected, TP53 depletion 138 caused a significant decrease of DINO levels, RB1 and E2F1 depletion did not cause significant 139 changes of DINO levels in control (siC: 1.00 +/-0.12; siRB1: 1.15 +/-0.03, p = non-significant 140 (ns) and siE2F1: 0.96 +/-0.14, p = ns) or HPV16 E7 expressing cells (siC: 6.64 +/-0.52, siRB1: 141 5.58 +/-0.56, p = ns and siE2F1: 6.15 +/-0.04, p = ns) ( Figure 3D ). The DINO locus is in close 9 H3 lysine 27 (H3K27) demethylase , KDM6A (31, 32). Hence, we next tested whether DINO 144 expression is also regulated by KDM6A. Consistent with previous reports (32, 33), we found that 145 KDM6A expression was increased in E7 expressing cells. Moreover, DINO expression was 146 significantly decreased upon KDM6A depletion (C: 0.61 +/-0.09, p < 0.01 and E7: 2.83 +/-0.17, 147 p < 0.001) ( Figure 3D ). Hence, HPV16 E7 causes increased DINO expression through a 148 mechanism that involves KDM6A mediated de-repression. 149 150
Heightened metformin sensitivity of HPV16 E7 expressing cells is reversed upon depletion 151 of DINO 152
Our research group has previously reported that HPV16 E7 expressing fibroblasts are sensitized 153 to undergo cell death under conditions of serum starvation. This response was shown to be TP53 154 dependent since it was abrogated by co-expression of the HPV16 E6 protein or a dominant 155 negative TP53 minigene (18, 20) . Given our results that DINO is critical to TP53 stabilization 156 and activation in HPV16 E7 expressing cells, we next wanted to determine whether vulnerability 157 of HPV16 E7 expressing cells could be controlled by modulating DINO levels. Since 158 keratinocytes are grown in serum free media, we first needed to define conditions that may 159 mimic growth factor deprivation in keratinocytes. We evaluated metformin, a drug that induces 160 metabolic stress by activating AMPK, inhibiting mTOR and mitochondrial respiratory complex 161 I, and depleting glycolytic and TCA cycle intermediates (34-37). Our results show that HPV16 162 E7 expressing HFKs are more vulnerable than control HFKs when subjected to metformin 163 treatment (C: 24.78 +/-1.12 and E7: 68.48 +/-0.38, p < 0.001) ( Figure 4A The TP53 tumor suppressor is a central hub that integrates various cellular stress signals and 181 triggers appropriate cytostatic and cytotoxic responses. In normal cells, TP53 has a very short 182
half-life and is present at low levels because the TP53 regulated MDM2 ubiquitin ligase targets 183 In contrast, however, depletion of the H3K27 demethylase KDM6A, which is expressed at 204 higher levels in E7 expressing cells, causes a significant decrease in DINO. Hence our results, 205 suggest a model whereby E7 mediated upregulation of KDM6A provides the initial trigger for 206 DINO induction. Our current results cannot distinguish, however, whether, similar to the 207 proximal CDKN1A locus (28, 32), DINO expression is directly de-repressed through KDM6A 208 mediated H3K27 demethylation, or whether this involves an indirect mechanism. It is noted, 209 however, that DINO and CDKN1A are distinct genetic loci and are expressed from opposite 210 strands in divergent directions (28). According to our model, the initial KDM6A mediated 211 increase in DINO expression causes TP53 stabilization and activation, which in turn causes a 212 further increase in DINO and TP53. Since E7 will also cause increased expression of p14 ARF as a 213 consequence of RB1 degradation and E2F activation, this may impair MDM2 activity and cause 214 a further increase in TP53 and DINO ( Figure 5) . Importantly, this model, where the initial 215 trigger of DINO expression is through KDM6A, accommodates the finding E7 expression can 216 cause increased TP53 levels in p19 ARF deficient mouse embryo fibroblasts (21). 217
218
Having established DINO as the key mediator of elevated TP53 levels in E7 expressing cells, we 219 next wanted to determine whether DINO may not only modulate TP53 levels but also a known 220 TP53 dependent biological phenotype of HPV16 E7 expressing cells. We previously discovered 221 that, similar to adenovirus E1A or MYC, HPV16 E7 expressing primary cells undergo cell death 222 when deprived of growth factors (17, 20, (40) (41) (42) . This form of cell death is triggered by 223 conflicting growth signals; the proliferative signal generated by oncogene expression that clashes 224 with the antiproliferative signal as a consequence of serum deprivation. This likely represents a 225 cell-intrinsic, innate tumor suppressive response that has been dubbed the "trophic sentinel 226 response" (43). In the case of HPV16 E7, this response is TP53 dependent and is overridden by 227 co-expression of the HPV16 E6 oncoprotein (18, 20) . 228 229 Serum deprivation is not a practicable approach to induce metabolic stress in keratinocytes, the 230 normal host cells of HPVs, since they are grown in serum free media. Hence, we evaluated other 231 means of generating metabolic stress and used metformin, a member of anti-diabetic biguanide 232 compounds that are evaluated for repurposing as cancer therapeutic and/or chemoprevention 233 drugs. Metformin treatment of control and HPV16 E7 expressing keratinocytes revealed that, compared to parental cells, HPV16 E7 expressing cells are more sensitive to metformin 235 treatment and that DINO depletion abrogates this sensitivity. 236 237 Similar to microRNAs, lncRNA activity can be modulated by nucleic acid based inhibitors and 238 mimics and it will be interesting to determine whether DINO based compounds may be 239 developed that could be used to modulate the clinical response to drugs that cause metabolic 240 stress in cancer cells, particularly in cancer such as HPV associated cancer where TP53 is not 241 mutated. and 5'-gggctcagagaagtctggtg -3'(reverse); CDKN1A: 5'-catgtggacctgtcactgtcttgta -3'(forward) 318 and 5'-gaagatcagccggcgtttg -3'(reverse); RPLP0:5'-atcaacgggtacaaacgagtc -3'(forward) and 5'-319 cagatggatcagccaagaagg -3'(reverse). The expression data shown was quantified using the ΔΔCT 320 method by normalizing all the qPCR targets against a housekeeping gene, RPLP0. 321 322
Cell viability 323
Cell viability was assessed using a resazurin assay, as previously described (48). At the day of 324 cell viability reading, cells were incubated with fresh media containing 10 μg/ml resazurin 
